Neuronostics

Neuronostics operates at the intersection of neurological diagnostics, medical devices and digital health, with a specific emphasis on extracting additional clinical value from EEG data. Its core differentiator is BioEP, a cloud-based decision-support platform that uses mathematical modelling to assess seizure susceptibility and support epilepsy diagnosis even when epileptiform activity is absent. The company is also developing ConnectEP for patient-generated seizure, medication and lifestyle records, giving it a broader data strategy than a single diagnostic workflow. Its stated development scope covers diagnosis, prognosis and paediatric applications, while the Stratus alliance provides a route toward US EEG-service integration pending regulatory clearance. The available comparable-company records identify only duplicate Neuronostics entries rather than distinct competitors, so a precise peer ranking is not possible. Neuronostics nonetheless appears differentiated from general digital therapeutics and consumer symptom-tracking businesses by combining EEG analytics, clinical reporting and research-oriented biomarker development. Its main commercial constraint remains the need to translate research and mathematical modelling into validated, regulated clinical products.

Neuronostics has progressed from grant-supported academic spin-out to a better-capitalized clinical technology company. Founded in 2018, it initially built its platform through Innovate UK grants, including awards dated Sep 1, 2018, May 20, 2020 and Jun 1, 2020, as well as an $1,127,986 grant from the National Institute for Health and Care Research in 2020. Equity financing became more substantial with a $413,506 seed round in 2021, a $606,900 seed round in 2023 and a $2,654,189 round on Apr 5, 2024. The largest disclosed financing arrived on Jun 30, 2026: a $3,969,866 seed round plus a $529,315 grant, bringing total disclosed funding to $10,242,678. Product development has expanded from BioEP’s EEG-based diagnostic decision support to the EEG Reading Service and ConnectEP patient-monitoring app. The 2025 Stratus alliance and its 2026 expansion are important inflection points because they connect the technology to a US clinical distribution pathway. Hiring for medical, research and product roles indicates an effort to convert technical progress into clinical validation and market readiness.